4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

EFFECT - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

S-1 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

DEF 14A - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

PRE 14A - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program JUPITER, FL, July 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) today announced that it has entered into a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002. The transaction has a potential value of up to $100 million, including milestone payments, and expands Jupiter from a single-program company into a dual clinical-stage CNS developer. Management believes the transaction strengthens the Company through diversification acr

TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE:MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has entered into a definitive license agreement (the "Agreement") on July 20th, 2026 with Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter"), under which PharmAla has granted Jupiter an exclusive, perpetual, royalty-bearing license to develop, manufacture and commercialize ALA-002, PharmAla’s lead drug candidate, in the United States. PharmAla retains all rights to ALA-002 outside the United

Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth JUPITER, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter Neurosciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced the appointment of Tomas J. Philipson, Ph.D., a distinguished health care economist and former Acting Chairman of the White House Council of Economic Advisers, to its Board of Directors, effective June 26, 2026. Dr. Philipson will serve on both the Audit Committee and Compensation Committee, bringing unparalleled expertise in health economics, reg

MIAMI, June 10, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Presenting Today – Wednesday June 11, 2026 8:30Virtual Lobby opens.Register for the Conference. If you already registered,

MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayJune 10, 2026 8:30Virtual Lobby opens.Register for the Conference. If you already registered, go back to

Investigational Oral Candidate JOTROL™ Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage biopharmaceutical company developing investigational therapies for neurodegenerative diseases, today announced that patient enrollment is now underway in its Phase 2a RESET clinical trial (NCT07592767) for JOTROL™ (investigational trans-resveratrol micellar formulation) in Parkinson's Disease (PD), with first patient dosing expected in the near term. Parkinson's Disease affects an estimated 1.1 million people in the United States, with roughly 90,000 new

Cash Runway Extended to Finance the Parkinson's Program; Debt Paydown Improves Shareholder Equity Position  Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced the closing of its registered direct offering, pursuant to the securities purchase agreements with certain investors, for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering were approximately $2.0 million (the "Offering"). "Yesterday's capital raise helps the Company p

Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering"). D. Boral Capital LLC is acting as the exclusive placement agent for the Offering. The closing of the Offering is expected to occur on or about May 21, 2026, subject to the satisfaction of customary closing conditions. T

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE:MDMA, OTCQB:MDXXF) ("PharmAla" or the "Company"), a global leader in the research, development, and manufacturing of novel MDXX-class molecules, today announced that it has entered into a term sheet (the "Term Sheet") under which PharmAla would grant Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter") exclusive, perpetual United States licensing rights to ALA-002, PharmAla's lead drug candidate and a next-generation, non-racemic MDMA Novel Chemical Entity. The total potential value of the proposed transaction is in excess of US$100 million through a combination of upfront consideration, development milestone pa

Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced that it has entered into term sheet to acquire exclusive, perpetual United States licensing rights to ALA-002, the lead drug candidate of PharmAla Biotech Holdings Inc. (CSE:MDMA, OTCQB:MDXXF) ("PharmAla"), a global leader in the research, development, and manufacturing o

Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth JUPITER, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter Neurosciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced the appointment of Tomas J. Philipson, Ph.D., a distinguished health care economist and former Acting Chairman of the White House Council of Economic Advisers, to its Board of Directors, effective June 26, 2026. Dr. Philipson will serve on both the Audit Committee and Compensation Committee, bringing unparalleled expertise in health economics, reg

New Advisors Bring Nationwide Pharmacy and Wellness Distribution Expertise to Nugevia™ Consumer Longevity Line Compounding Pharmacy and Wellness Channels Represent Over $1.5 Billion Addressable Market for Practitioner-Grade Nutraceuticals in the U.S. JUPITER, FL, April 07, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the appointment of Kristopher Fishman and Sanjiv Lal to the Nugevia™ Advisory Board. The two bring direct distribution relationships across compounding pharmacies and wellness channels, an addressable market th